Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia

NCT06756022 is registered in ClinicalTrials.gov with Anhui Provincial Children's Hospital as lead sponsor.

NCT NCT06756022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06756022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia
Lead sponsor
Anhui Provincial Children's Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 21, 2024
Completion date
December 31, 2025
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced nausea and vomiting